We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Meta-Analysis Links Diabetes to Increased Blood Cancer Risk

By LabMedica International staff writers
Posted on 21 Jun 2012
According to a new, worldwide meta-analysis, patients with type 2 diabetes have a significantly increased risk of developing certain types of blood cancers.

A collaborative study led by researchers at The Miriam Hospital (Providence, RI, USA) analyzed 26 (13 case-control and 13 cohort) published observational studies that had evaluated the association between diabetes mellitus type 2 and the incidence of lymphoma, leukemia, and myeloma. More...
The meta-analysis included more than 17,000 cases of type 2 diabetes and blood cancer worldwide. The researchers concluded that patients with type 2 diabetes have about 20% increased risk of developing leukemia, myeloma, and non-Hodgkin lymphoma, as well as a subtype of non-Hodgkin lymphoma known as peripheral T-cell lymphoma. They did not find any associations with Hodgkin lymphoma. The findings suggest type 2 diabetes could be associated with approximately 5% of all incidents of leukemia, myeloma, and non-Hodgkin lymphoma.

The researchers also found that the risk of lymphoma, leukemia, and myeloma appears to differ depending on the geographic region of the original report. For example, the risk of non-Hodgkin lymphoma was higher in Asia and Europe, while there was an increased leukemia risk in the United States and Asia.

“When you consider that [millions of people have type 2 diabetes and that millions more are still likely to develop it], a 20% increased risk of blood cancer is quite significant,” noted lead author Jorge Castillo, MD, a hematologist-oncologist with The Miriam Hospital. He added, “It’s important to remember that type 2 diabetes can, to some degree, be prevented and controlled through lifestyle modification, such as diet and exercise; so by preventing the onset of type 2 diabetes, we could also prevent blood cancer.” Dr. Castillo and colleagues suggested that, in addition to studying antidiabetic therapy, future research should focus particularly on evaluating roles of behavioral factors such as obesity, physical activity, dietary habits, and smoking, which have been linked to both diabetes and cancer.

The findings, published online May 24, 2012, in the American Society of Hematology journal Blood, add to the growing evidence base linking diabetes and certain types of cancer.

Related Links:

The Miriam Hospital



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.